Literature DB >> 31090647

Current practices in deceased organ donor management.

Madhukar S Patel1, Peter L Abt2.   

Abstract

PURPOSE OF REVIEW: Optimizing the management of deceased organ donors focuses on providing critical care that prevents, mitigates, or repairs the pathophysiologic sequelae of brain death. This review discusses protocol-based care; approaches to monitoring, resuscitation, hormone replacement therapy, and respiratory management; and the potential of various additional donor therapies. RECENT
FINDINGS: Protocol-based critical care after the determination of brain death has the potential to substantially increase the quantity and improve the quality of organs available for transplantation. Close hemodynamic monitoring with timely resuscitation using isotonic fluid replacement as well as adjunctive vasoactive and hormone replacement therapy in the persistently hemodynamically unstable donor is recommended. Convincing evidence suggests that mild therapeutic hypothermia of the donor can be adopted to reduce delayed graft function in the renal transplant recipient.
SUMMARY: There continues to be a limited number of current published reports pertaining to deceased organ donor management, with many practices still based on consensus statements. Recent endorsement and recommendations for conducting donor intervention research have provided a framework for future studies, which have potential to lead to the publication of quality results so that more evidence-based guidelines can be developed.

Entities:  

Mesh:

Year:  2019        PMID: 31090647     DOI: 10.1097/MOT.0000000000000638

Source DB:  PubMed          Journal:  Curr Opin Organ Transplant        ISSN: 1087-2418            Impact factor:   2.640


  2 in total

Review 1.  Organ procurement in a deceased donor.

Authors:  Hong Pil Hwang; Jong Man Kim; Sung Shin; Hyung Joon Ahn; Sik Lee; Dong Jin Joo; Seung Yeup Han; Seok Jin Haam; Jeong Kye Hwang; Hee Chul Yu
Journal:  Korean J Transplant       Date:  2020-09-30

2.  Itaconic acid facilitates inflammation abatement and alleviates liver ischemia-reperfusion injury by inhibiting NF-κB/NLRP3/caspase-1 inflammasome axis.

Authors:  Ensi Ma; Hao Xing; Jiahao Pei; Quanbao Zhang; Ruidong Li; Conghuan Shen; Yifeng Tao; Jianhua Li; Zhenyu Ma; Jing Zhao; Zhengxin Wang
Journal:  Ann Transl Med       Date:  2022-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.